Scalper1 News
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it’s bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH, afflicts as much as 10% of U.S. adults, but most don’t realize it. It’s completely unrelated to viral hepatitis, but they share the name because of the shared symptom of inflamed liver. “Steato” means Scalper1 News
Scalper1 News